Biosimilar infliximab use in paediatric IBD by Richmond, Lisa et al.
  89Richmond L, et al. Arch Dis Child 2018;103:89–91. doi:10.1136/archdischild-2017-313404
D
rug therapy
Short report
Biosimilar infliximab use in paediatric IBD
Lisa Richmond,1 Lee Curtis,1 Victoria Garrick,1 Pam Rogers,2 
Michelle Wilson,3 Rachel Tayler,1 Paul Henderson,2,3 Richard Hansen,1 David C Wilson,3 
Richard K Russell1
AbStrAct
background Biosimilar infliximab became available 
in the UK in 2015. Paediatric experience to date on its 
use is limited. We prospectively evaluated the safety 
and efficacy of biosimilar infliximab (Remsima) in two 
paediatric gastroenterology networks in patients with 
inflammatory bowel disease.
Methods Prospective clinical data were collected from 
laboratory reports, electronic patient records and case 
notes of 40 patients starting Remsima for the first time. 
Disease activity scores together with blood and stool 
biomarkers were used to assess response.
results Our data set highlights that Remsima was 
associated with a significant clinical and biochemical 
improvement (p<0.01 or less for all parameters 
assessed) in Crohn’s disease post induction. There were 
no significant safety issues noted. The total cost saving 
was £47 800, representing a 38% reduction from 
originator.
conclusion We found that biosimilar infliximab is as 
effective as originator infliximab and its use is associated 
with significant cost savings.
IntroDuctIon
There are an increasing number of patients with 
paediatric inflammatory bowel disease (PIBD) 
commencing antitumour necrosis factor (TNF) 
therapy in the form of infliximab.1 Infliximab is 
commonly used in PIBD for chronically active 
disease, which is not controlled by ‘conventional’ 
therapy, fistulising perianal Crohn’s disease (CD) or 
for acute severe colitis as an alternative to colec-
tomy.2 Initial PIBD use was limited due to the lack of 
a specific paediatric licence for Remicade, its signif-
icant cost and the potential safety profile, specifi-
cally malignancy.
In early 2015, European Medicine Agency 
licence approval was granted for biosimilar inflix-
imab use in PIBD from initial studies in adults with 
rheumatological conditions. Biosimilar infliximab 
is available for use in the UK either as Remsima 
or Inflectra. Since the initial studies satisfying the 
criteria for biosimilarity are in adult rheumatology 
and did not use standard inflammatory bowel 
disease dosing strategies, an urgent need developed 
for PIBD-specific data, focusing both on safety and 
clinical effectiveness.
There is also the added opportunity for signifi-
cant cost savings, which may in turn allow easier 
access to therapy. A prospective safety, efficacy and 
cost-effectiveness evaluation of biosimilar infliximab 
(Remsima) was carried out in two paediatric gastro-
enterology networks between 2015 and 2016.
PAtIentS AnD MethoDS
All patients with PIBD from the regional services 
in the West and South East of Scotland (based at 
the Royal Hospital for Children, Glasgow, and the 
Royal Hospital for Sick Children, Edinburgh) who 
required infliximab were started on Remsima. Data 
were collected at treatment initiation and response 
reviewed, following three induction doses, at around 
week 12 post initiation. In line with the licence, 
standard dosing at 5 mg/kg at 0, 2 and 6 weeks was 
used with infusions given over 2 hours. Patients were 
routinely given hydrocortisone at 4 mg/kg (maximum 
dose 200 mg) prior to each Remsima infusion. No 
consistent phial sharing protocols were used for the 
duration of this evaluation. Prospective clinical data 
were collected from local laboratory reports, elec-
tronic patient records and case notes of patients 
starting Remsima. Our intention was that all patients 
were anti-TNF-naïve at initiation.
Clinical disease activity indices, namely the 
weighted Paediatric Crohn’s Disease Activity Index3 
and Paediatric Ulcerative Colitis Activity Index,4 
were used to document disease activity at initia-
tion and follow-up. For analysis purposes, calpro-
tectin samples and C reactive protein values were 
limited to laboratory-reported maximum and 
minimum assay values (>1800 μg/g and <1 mg/L, 
respectively). An adequate infliximab trough was 
deemed to be in the range of 3–7 mg/L. Levels and 
antibodies were measured routinely and were not 
dependent on clinical status.
Data were expressed as median with range. Statis-
tics were calculated using Microsoft Excel (Micro-
soft Corporation, Redmond, Washington, USA) 
and GraphPad V.3 software (GraphPad Software, 
La Jolla, California, USA). Ethical approval was 
not required as this was an evaluation of clinical 
practice. Average costings for a phial of biosimilar 
and originator infliximab (Remsima and Remi-
cade, respectively) were obtained from the recent 
award of a national framework agreement by 
National Procurement Scotland (OJEU, contract 
award notice: http:// ted. europa. eu/ udl? uri= TED: 
NOTICE: 92352- 2015: TEXT: EN: HTML). The 
cost saving was then calculated by adding the total 
number of phials used and calculating the cost 
saving on each phial multiplied by this difference.
reSultS
Forty consecutive patients (60% male) 
started Remsima between August 2015 and June 
2016, equating to 190 infusions in total. Twen-
ty-nine patients had CD and 11 ulcerative colitis 
(UC)/inflammatory bowel disease unclassified 
(IBDU). The median age of patients (IQR) at 
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diagnosis was 12.7 years (10–14) and 13.7 years (13–16) at 
Remsima initiation.
The primary reasons for treatment in CD were active luminal 
disease 76% (22/29), perianal disease 14% (4/29) and with other 
indications 10% (3/29). For UC/IBDU, chronic refractory disease 
was the indication in 64% (7/11) and acute severe colitis in 36% 
(4/11). The majority (95%; 38/40) of patients were on coimmu-
nomodulator therapy; 71% (27/38) on azathioprine/mercapto-
purine and 29% (11/38) on methotrexate. All patients received 
intravenous hydrocortisone pre-Remsima dosing. At initiation 
43% (17/40) were also on oral prednisolone. Remsima was asso-
ciated with a significant clinical and biochemical improvement 
in CD postinduction (table 1). Infliximab levels and antibodies 
were recorded for 50% (20/40) of patients following induction 
(figure 1). The median trough level was 3.85 mg/L (IQR 1.60–
4.98) and 10/20 (50%) samples had a level outside the targeted 
therapeutic range.
Only two patients had positive antibodies recorded, one of 
whom experienced an acute infusion reaction (AIR). This gives 
an AIR per infusion rate of 1/190 (0.5%) and AIR per patient 
1/40 (2.5%) from this cohort. Immediately after the second 
Remsima infusion began, the patient’s face became flushed and 
the throat felt tight. The infusion was discontinued and therapy 
was subsequently changed from Remsima to adalimumab. 
Infliximab levels on this patient were recorded as 25.9 mg/L 
with strongly positive antibodies. This patient had in fact been 
exposed to Remicade 6 years previously with mild sensitivity. 
There were no additional safety issues recorded.
The average cost saving per phial during this period was 
approximately 38% reduction from the originator (Remicade) 
to the biosimilar (Remsima). For the total number of infusions 
carried out during this evaluation, we estimate a conservative 
cost saving of around £47 800 (€57 000).
DIScuSSIon
The benefits of infliximab treatment for PIBD are well estab-
lished and represent a cornerstone of PIBD practice for patients 
with inadequate or lost response to first-line and second-line 
therapy. Published studies to date have described outcomes using 
originator infliximab (Remicade). These data have shown that 
early clinical response and remission rates following an induc-
tion course of Remsima match those of historical patients treated 
with infliximab (Remicade).1 To date, there is a paucity of data in 
the paediatric literature on biosimilar use, with none published 
from the UK5 and none as robust as the current study, which 
prospectively collected clinical and laboratory data as part of 
good clinical practice. Recent guidelines have generally advised 
caution in the use of biosimilar anti-TNFs until further data on 
their use have become available6; we hope this study will help 
support their wider introduction into paediatric practice.
Continued close monitoring of these patients is necessary to 
collect longer term data and to evaluate maintenance of remis-
sion, secondary loss of response and safety. The financial benefits 
of using these treatments are clear from this and other studies, 
but will only be upheld if long-term maintenance rates match 
these initial clinical response rates. As the emerging data for 
treatment-naive patients are published, the logical next step is to 
look at switching those already established on originator inflix-
imab to biosimilars. Early paediatric data on this are encour-
aging, but more detailed information on patient outcomes, 
including trough drug levels and antibodies, is awaited.7 The 
trough level data from this study showed a wide range of values 
with several below the quoted therapeutic range. Although we 
attempted to collect these data in all patients, there may be a 
slight bias in the samples we collected towards patients with 
signs of limited/no response to infliximab. This may be reflected 
in the fact that 40% of the results were subtherapeutic. Impor-
tantly there were no signs of significant allergenicity.
In summary, we have demonstrated that biosimilar infliximab 
is as safe and effective as originator infliximab in the short-term 
using data from two regional referral centres.
There are also significantly associated cost savings. These 
baseline data have now enabled us to confidently switch patients 
from originator to biosimilar, adopting the same prospective 
methodology to monitor effectiveness, safety and cost.
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table 1 Characteristics of patients at initiation and 12-week follow-
up
clinical data At initiation At 12-week review
comparative 
p Value
ESR, median (IQR) 16 (7.5–31.3) (n=40) 5 (2.25–10) (n=26) p=0.0009
CRP, median (IQR) 5.5 (2–21.3) (n=40) 1 (1–2) (n=27) p=0.0004
Albumin, median (IQR) 35 (30.8–38) (n=40) 38 (36–41) (n=27) p=0.002
Calprotectin, median 
(IQR)
840 (618.3–1642.5) 
(n=34)
250 (60–760) (n=17) p=0.008
wPCDAI, median (IQR) 27.5 (7.5–55) (n=29) 5 (0–20) (n=21) p=0.002
PUCAI, median (IQR) 45 (40–55) (n=11) 23.8 (8.1–60) (n=6) p=0.4
Disease classification 
(Crohn’s)
% (n/N)
Remission, 28% (8/29) Remission, 67% 
(14/21)
p=0.002
Mild, 31% (9/29) Mild, 28% (6/21) p=0.9
Moderate, 28% (8/29) Moderate, 0% (0/21) p=0.02
Severe, 13% (4/29) Severe, 5% (1/21) p=0.6
CRP, C reactive protein; PUCAI, Paediatric Ulcerative Colitis Activity Index; wPCDAI, 
weighted Paediatric Crohn’s Disease Activity Index.
Figure 1 Infliximab levels at week 14 following induction.
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